Summary: A homogeneous enzyme immunoassay for the determination of methotrexate in serum (EMIT, Syva Corp.) was fully mechanized by the use of an Eppendorf analyzer 5010. Coefficients of variation from day to day were in the range 2-16%. A comparison of the results obtained by EMIT and a radioimmunoassay (Methotrexate 125 I Radioimmunoassay Kit, Diagnostic Biochemistry Inc.) in a series of 50 samples from patients showed a good correlation between both methods. The specificity of the EMIT assay appeared to be adequate. The time required for the determination of about 20 patient samples by this procedure was only about 80 minutes. From our clinical experience the EMIT assay appears to be well suited for routine monitoring of methotrexate serum concentrations above 0.1 μπιοΐ/l during intrathecal and high dose methotrexate therapy. 
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Bestimmung von Methotrexat im Serum mit einem rasch durchf hrbaren, vollmechanisierten Enzymimmunotest (EMIT)
Zusammenfassung: Ein homogener Enzymimmunotest
Introduction
Methotrexate^), an inhibitor of dihydrof late reductase (EC 1.5.1.3), is widely used in the chemotherapy of various ne plastic diseases, such as breast cancer, acute leucaemia or osteogenic sarcoma, and in the treatment of nonrfieoplastic disorders such as severe psoriasis (1) . With systemic and intrathecal regimens for methotrexate in current use, serious toxicities such as myelosuppression, gastrointestinal mucositis, renal failure and neuro-*) Parts of this study have been reported at "Kongre der Deutschen Gesellschaft f r Laboratoriumsmedizin" in Berlin 1979. toxicity have been observed (1) . Especially patients who receive high-dose methotrexate regimens risk the development of life-threatening side reactions. Toxicity occurs if certain thresholds for the duration of methotrexate exposure and the serum concentration of this compound are exceeded. For bone marrow and gastrointestinal epithelium, for example, these thresholds appear to be 0.02 jumol/1 and about 42 hours (1) . The severity of toxicity depends more on the extent to which the timethreshold is exceeded than on the magnitude of the elevation of the methotrexate concentration above the concentration-threshold (1). According to the literature serum methotrexate levels < 5-10 μτηοΙ/1 at 24 hours (2, 32), < 0.5-1.0 μπιοΐ/l at 48 hours (2-4) and < 0.05 jumol/1 at 72 hours (2) after initiation of the methotrexate therapy point to an adequate' serum methotrexate clearance and usually will not produce toxicity.
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Monitoring of serum niethotrexate concentrations may be helpful in the identification of patients with elevated methotrexate levels. Life-threatening side reactions may then be averted by administration of the antidote citrovorum factor (5-formyltetrahydrofolate; trade name: leucovorin), and by taking measures to improve renal methotrexate excretion, such as intravenous hydration and alkalinization of the urine (1). Furthermore, the methotrexate serum levels can be monitored, so that the administration of citrovorum factor is continued until the methotrexate concentration has fallen below the toxicological relevant borderline at about 0.08-0.1 μτηοΐ/ΐ (1), preferably below 0.01 μιηοΐ/ΐ (3, 5) .
Monitoring of serum methotrexate levels has been recommended recently by various authors (1-7). So far, for the determination of methotrexate, relatively complex microbiological (7), fluorometric (8, 9) , enzymatic (10, 11) and high-pressure liquid Chromatographie (12,13) methods have been used. A disadvantage of competitive protein binding assays (14, 15) and radioimmunoassays (16, 17) is that these methods require the use of radioactive material. Recently a homogeneous enzyme immunoassay for the determination of methotrexate (18) has become commercially available (EMIT Methotrexate Assay, Syva Corp., Palo Alto, U.S.A.). In the present study we report on an evaluation of a mechanized version of this EMIT assay and our preliminary clinical experience with this test.
Material and Methods

Origin of specimens
Serum samples (n = 168) containing methotrexate were obtained from patients with various neoplastic diseases such as breast cancer, acute lymphocytic leucaemia and osteogenic sarcoma.
Materials
The reagents for the enzyme immunoassay (EMIT), the determination of aspartate aminotransferase (EC 2.6. 
Enzyme immunoassay (EMIT)
The original procedure of the EMIT methotrexate assay was fully mechanized by adapting this test to the Eppendorf analyzer 5010 (Eppendorf, D-2000 Hamburg) in the same way as previously described for the EMIT assays of phenobarbital, phenytoin and theophylline (19, 20 
Results and Discussion
Precision
The coefficients of variation from day to day were 2-16% with EMIT (tab. 1) and with the radioimmunoassay about 10% (mean value with standard deviation: 1.02 ± 0.11 μιηοΙ/1, number of contributing values: 5). The precision data of EMIT and radioimmunoassay refer to mean values of duplicate determinations and single determinations respectively. 
Accuracy
The recovery of methotrexate added to drug-free pooled human serum (concentration range 0.3-1.9 μπιοΙ/1) with EMIT was 100-107%, and with the radioimmunoassay was 105-120% (tab. 2).
Furthermore the results measured by EMIT and radioimmunoassay in 50 specimens from patients were compared. The correlation between the results was good (r = 0.974). The slope of the line and the intercept were calculated by use of the standardized principal component analysis (21, 22) , which in contrast to the classical regression analysis represents a bivariate procedure. The slope of the line points to a proportional difference of about 10% ( fig. 1 ). Accordingly the mean value of the results obtained by EMIT (y: 0.48 ± 0.36 jumol/1) was significantly lower than that of the values determined by radioimmunoassay (x: 0.53 ± 0.40 μτηοΐ/ΐ; t-value 3.45, ρ <°0.0025). This discrepancy appears to be due to the elevated recovery of me<thotrexate by the radioimmunoâ ssay (tab. 2). Reproducible deviations of more than 30% between the results of both assays occurred in 2 out of 50 cases. 
Specificity
The specificity of the EMIT assay was teste.d by the determination of the cross-reactivity of compounds structurally related to methotrexate and various other drugs. Aminopterin caused a relevant cross-reaction in this assay (tab. 3). This drug, however, is usually not administered together with methotrexate.
Folic acid, dihydrofolic acid, N 5 -formyltetrahydrofolate and N 5 -methyltetrahydrpfolate showed a noticeable cross-reactivity only at concentrations, which were about 3-5 orders of magnitude above the normal range for serum levels of folic acid and its derivatives (16 In accordance with the manufacturer (24) we observed that the metabolites of methotrexate, 4-amino-4-deoxy-N 10 -methylpteroic acid and 7-hydroxymethotrexate, which show only a relatively weak cytostatic effect (5), interfere distinctly at concentrations above 0.4 μπιοΐ/ΐ and 90 /zmol/l respectively (tab. 3). As 7-hydroxymethotrexate levels were reportedly below 90 jumol/1 during high-dose methotrexate-therapy (13), a relevant interference of this metabolite usually appears to be improbable. It is not known whether serum 4-amino-4-deoxy-N 10 -methylpteroic acid (25) occurs in sufficiently high concentration to cause an interference.
With the remaining substances tested (tab. 3) no relevant cross-re activity was observed.
Interferences
In spiked serum samples bilirubin (up to 600 μτηοΐ/ΐ), haemoglobin (up to 10 g/1) and triglycerides (up to 12 mrnol/1) caused deviations of less than 10% from the expected methotrexate values in the EMIT assay.
Detectability
The detection limit of methotrexate by EMIT was approximately at 0.1 μτηοί/Ι. At this methotrexate concentration a coefficient of variation of about 30% (mean value: 0.11, n = 10) was found within series. Though the detection limit of the EMIT assay is about 3 orders of magnitude above that of the radioimmunoassay, the EMIT assay usually appears to be sensitive enough for routine monitoring of methotrexate concentrations during the first decisive 48-72 hours after high dose administration of methotrexate, or the time until the level of this drug has fallen below 0.1 μπιοΐ/l. As methotrexate, however, inhibits DNA synthesis in bone marrow and intestinal epithelium at concentrations above 0.01 Mmol/l (26), it appears necessary to monitor methotrexate concentrations down to this level in patients showing manifest (3) or questionable toxicity. Theref ore the detectability of the EMIT assay has to be adequately improved.
Practicability and costs
Compared with the radioimmunoassay, the EMIT test showed better practicability. A disadvantage of the radioimmunoassay is that one or more dilutions have to be prepared from every sample, as the calibration curve ranges from 0.2-4.4 nmol/1. The time required for the determination of about 20 patients samples containing methotrexate concentrations within the clinically relevant range of 0.1-2.0 Afmol/1 is about 80 minutes by our fully mechanized modification of the EMIT assay, and approximately 270 minutes by radioimmunoassay. A single methotrexate determination for emergency situations can be performed by EMIT within 40 and by radioimmunoassay in about 80 minutes.
As already frequently pointed out (30, 31) , the EMIT technique has the advantage that contact with radioactive material is avoided, the reagents have a long shelflife and its mechanization is easy. Compared with the original procedure our fully mechanized version of the EMIT assay shows better practicability, a higher sample throughput per hour and a reduction of costs for reagents and technician time by about 20-40% (based on a series of 10-30 patients samples). The costs for a methotrexate determination including standards, control sera, reagents, pertinent supplies and technician time are about 14 DM per EMIT test and about 13 DM with the radioimmunoassay, for a series of 20 samples. A single methotrexate determination is much more expensive (tab. 4) .
Clinical experience
Methotrexate serum concentrations were determined by EMIT in samples from patients (n = 5) who repeatedly received an intrathecal injection of 25 mg methotrexate (= 12-16 mg/m 2 ) once a week because of diffuse, leptomeningeal infiltrations due to acute lymphocytic leucaemia, malignant lymphoma or breast carcinoma. With all of these patients only relatively low serum methotrexate concentrations were observed (tab. 5), and 48 hours after intrathecal administration of this compound methotrexate serum levels were always below 0.1 μχηοΐ/ΐ. Accordingly no relevant adverse reactions occurred with these patients. The serum methotrexate concentrations observed (tab. 5) after intrathecal injection of this substance are of the same order of magnitude as those described in the literature (28) .
The EMIT assay also appears to be well suited for monitoring of serum methotrexate levels during high-dose methotrexate therapy. In figure 2 the time course of the serum methotrexate concentrations in a 20 year old female patient with osteogenic sarcoma during and after the infusion of 250 ing/kg methotrexate is illustrated. Citrovoram factor (15 mg) was given as indicated every six hours. Intravenous hydration {glucose 50 g/1 (Travenol) 1500 ml/24 hours; ringer-lactate solution (Braun Mels ngen) 1500 ml/24 hours) and alkalinization (NaHCO 3 -solution 60 iramol/24 hours) was started 12 hours before the beginning of the methotrexate infusion and then maintained for a further 72 Hours. The creatinine clearance of the patient (132 ml/min) was in the normal range. The serum methotrexate levels at 24 and 48 hours after the beginning of the methotrexate infusion were below the corresponding toxicologically relevant borderlines of ΙΟμτηοΙ/Ι and 1.0 μπιοΐ/ΐ respectively. Accordingly no relevant adverse reactions were observed. At 72 and 96 hours, however, the serum methotrexate levels were distinctly above 0.1 μηιοΐ/l and a transient rise of alanine aminotransferase (up to 108 U/l) and of aspartate aimnptransferase (up to 63 U/l) occurred. A myelosuppression was not encountered. The methotrexate levels determined by EMIT at 24 and 48 hours were in accordance with those observed by other authors at the same dosage of this drug (1-4). The slightly elevated methotrexate concern trations at 72 and 96 hours might be due to a release of methotrexate from storage sites. Wang et al. observed in some patients even higher methotrexate plasma concentrations at 72 hours than at 48 hours, presumably due to such a phenomenon (29) .
During the terminal serum disappearance phase of methotrexate, following its high-dose administration, an increased concentration of methotrexate metabolites in the serum is to be expected (1) . This may be important in the genesis of toxic adverse reactions (1) and might cause an interference in enzyme-and radioimmunoassays for the determination of methotrexate (24, 25) . Therefore it appears necessary to investigate the serum concentrations of 4-amino-4-deoxy-N 10 -methylpteroic acid and 7-hydroxymethotrexate, the major metabolites of methotrexate, during this period. As high-pressure liquid chromatography has already been successfully applied to the determination of 7-hydroxymethotrexate (13) , it is planned to use this technique in further studies on serum concentrations of methotrexate metabolites.
Conclusion
Compared with other procedures used so far for methotrexate determination, the EMIT assay has the advantage that it can be more easily mechanized and rapidly performed. The detectability of the EMIT assay needs to be improved somewhat, in order to detect methotrexate concentrations above 0.01 /imol/l; relevant studies are in progress. Except for this limitation the EMIT assay proved to be dependable and appeared to be well suited for routine monitoring of serum methotrexate concentrations during intrathecal and high-dose methotrexate therapy.
